Streamlining staging of lung cancer with Whole Body MRI
Description
Design:
Multicentre comparison
Treatment:
All patients will undergo a whole body MRI in addition to the standard staging protocol employed at their institution.
Key inclusion/exclusion criteria:
Inclusion:
- Adult patients with suspected primary NSCLC on chest CT triggering staging/biopsy, or already histologically proven primary NSCLC
- Disease potentially radically treatable: stage IIIb or less on diagnostic CT (T1-4, N0-2, M0)
- WHO PS 0-2
Exclusion:
- Evidence of severe or uncontrolled systemic disease
- Contraindications to MRI
- Unequivocal metastatic or N3 disease on diagnostic CT chest and abdomen (including M1a disease, malignant pleural effusion)
- Further staging work up not indicated by MDT due to poor PS or patient choice
- Histologies other than NSCLC.
Duration of recruitment:
4 years (closed to recruitment on 5 September 2016).
Aim
This trial evaluates whether early WB-MRI increases per patient sensitivity for metastasis in NSCLC compared to standard NICE-approved diagnostic pathways.